A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma

NCT02939807 | Withdrawn Phase 2 DMC FDA Drug

• 3 other identifiers: 102418ABC-1061P01CA203628-01
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

This is a Phase II study of single agent ABC294640. Patients with advanced hepatocellular carcinoma (HCC) who have experienced tumor progression or unacceptable toxicity on single agent sorafenib will receive ABC294640 500 mg by mouth twice a day continuously. Patients will continue on study drug until the development of progressive disease per modified RECIST, intolerable toxicity, withdrawal of patient consent or other event as outlined in patient discontinuation.

Conditions

Carcinoma, Hepatocellular

Keywords

Yeliva™; hepatocellular carcinoma; ABC294640; hepatic neoplasms; liver neoplasms; hepatic cancer

Outcome Measures

Primary Outcomes (1)

• To assess objective response rate (per modified RECIST) of single agent ABC294640 in treatment of HCC

  Radiographic Assessment will be completed up to 28 days prior to registration and every 8 weeks (+/- 7 days) following registration until disease progression or other (e.g.toxicity, patient decision, etc). The baseline radiographic assessment will include CT or MRI of the chest, abdomen and pelvis. Subsequent imaging will include only those body regions that include measureable index lesions per modified RECIST. Radiographic assessments will be completed every 8 weeks (+/- 7 days). In regards to the end of treatment visit, if the patient is taken off study and already has radiographic documentation of progressive disease, completing the radiographic assessment at the end of treatment visit is not required per study. If the patient is taken off study for other reasons such as toxicity or patient decision, it is strongly recommended that a radiographic assessment be obtained.

  The primary endpoint is objective response rate (ORR) at 16 weeks defined according to modified RECIST criteria in second-line ABC294640 in patients with advanced HCC who have progressed on sorafenib.

Secondary Outcomes (12)

• To estimate the time to tumor progression (TTP) in HCC patients treated with ABC294640

  While on study, radiographic response will be documented every 8 weeks; after discontinuation, every 3 months for a maximum of 24 months after the last patient registered

• To estimate the overall survival (OS) in HCC patients treated with ABC294640

  Time interval from initiation of study treatment to death due to any cause. All patients should be followed every 3 months for survival for a maximum of 24 months after the last patient has been registered to the trial.

• To evaluate the pharmacokinetic behavior of ABC294640 in HCC patients [Peak Plasma Concentration (Cmax)]

  From Cycle 1 Day 1 through to prior to dosing in Cycle 2 Day 1. (Each cycle is 28 days)

• To evaluate the pharmacokinetic behavior of ABC294640 in HCC patients [Area Under the drug concentration over time curve, (AUC)]

  From Cycle 1 Day 1 through to prior to dosing in Cycle 2 Day 1. (Each cycle is 28 days)

• To describe the relationship between changes in marker levels of sphingolipids in peripheral blood in patients being given ABC294640

  Plasma samples for sphingolipid profiling will be drawn at baseline, on Cycle 1 Day 1 prior to and 8 hours post ABC dosing, and prior to dosing on Cycle 1 Day 15 and Cycle 2 Day 1, and within 1 hour prior to the pre- and post-treatment tumor biopsies.

Study Arms (1)

advanced HCC, tumor progression with sorafenib

EXPERIMENTAL

Patients with advanced HCC who have experienced tumor progression with sorafenib will receive ABC294640.

Drug: ABC294640

Interventions

ABC294640 DRUG

ABC294640 500 mg orally twice daily (approximately 12 hours apart) continuously. ABC294640 will be dosed under fasting conditions (at least 1 hour before or 2 hours after eating). A cycle is defined as 28 days.

Also known as: YelivaTM

advanced HCC, tumor progression with sorafenib

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient must have advanced hepatocellular carcinoma; fibrolamellar HCC is not allowed. Hepatocellular carcinoma will be confirmed by at least one of the following:
• Tissue diagnosis
• The presence of one or more liver lesions measuring 2 cm in longest diameter, showing characteristic arterial enhancement and venous washout using arterial-phase contrast enhanced imaging, and a clinical history of cirrhosis.(1)
• Voluntary signed and dated institutional review board (IRB) approved informed consent form in accordance with regulatory and institutional guidelines.
• Documented progression or intolerance to sorafenib as determined by the enrolling investigator:
• Patient must have at least one measurable untreated lesion as per modified RECIST criteria. Measurable disease may include extrahepatic lesions. Abdominal imaging should employ a "liver protocol" image capture technique. The following are not considered measurable lesions: bone lesions, ascites, and pleural effusions. Prior RFA, PEI, or TACE of non-target lesions is allowed.
• Time interval for last local therapy (radiofrequency ablation, percutaneous ethanol injection, radiotherapy, transarterial chemoembolization) more than 4 weeks prior to registration.
• Life expectancy of at least 12 weeks.
• years of age or older.
• ECOG performance status of 0-2.
• Child-Pugh Cirrhotic Status A or B with a score of 7.
• Acceptable liver function:
• Bilirubin ≤ 3 times upper limit of normal (CTCAE Grade 2 baseline)
• AST (SGOT), ALT (SGPT) 3 x ULN (CTCAE Grade 1 baseline)
• Acceptable kidney function:

You may not qualify if:

• New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG.
• Underlying psychiatric disorder requiring hospitalization within the last two years or a HADS score of 11 or more.
• Clinically significant neurological disorder (Parkinson's disease, dementia, multiple sclerosis), as determined by the enrolling investigator
• Active, uncontrolled bacterial, viral or fungal infection, requiring systemic therapy.
• Pregnant or nursing women. NOTE: Women of childbearing potential and men must agree to use adequate contraception or abstinence prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
• Treatment with radiation therapy, surgery, or investigational therapy within one month prior to registration.
• More than two lines of prior systemic therapy for HCC
• Unwillingness or inability to comply with procedures required in this protocol.
• Known infection with HIV.
• Hepatitis C on protease therapy.
• Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the Investigator.
• Patients who are receiving drugs that are sensitive substrates of CYP450 1A2, 3A4, 2C9, 2C19 or 2D6, or strong inhibitors or inducers of all major CYP450 isozymes that cannot be stopped at least 7 days or 5 half-lives (whichever is longer) before starting treatment with ABC294640 and either replaced with another appropriate medication or not given for the duration of the clinical study. (A list of commonly used drugs that are sensitive substrates of CYP450 1A2, 3A4, 2C9, 2C19 or 2D6, or strong inhibitors or inducers of all major CYP450 isozymes with the half-life of each drug identified, is included as an Appendix C)
• A history of CTC Grade 3 bleeding esophageal or gastric varices within the past 2 months. Prior variceal bleed is permitted if patient has undergone banding or sclerotherapy and there has been no evidence of bleeding for 2 months. Patients at risk for varices (based on the following: known history of esophageal or gastric varices; evidence of hepatic cirrhosis and/or portal hypertension including biopsy-proven cirrhosis, hypersplenism, or radiographic findings of varices) will be screened (using either esophagogastroduodenoscopy (EGD) or capsule endoscopy) for esophageal varices, unless such screening has been performed in the past two years from study entry and the patient is receiving medical treatment for prophylaxis of variceal bleeding, such as non-selective beta blockade. If varices are identified that require intervention (banding), patient will not be eligible until varices are adequately treated. Patients presenting with gastric varices will not be eligible for the study.
• Patients who are currently taking Coumadin or Coumadin derivatives.
• Patients who are currently participating in any other clinical trial of an investigational product.

Sponsors & Collaborators

• Medical University of South Carolina: lead
• National Cancer Institute (NCI): collaborator
• Apogee Biotechnology Corporation: collaborator

Study Sites (1)

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Location

MeSH Terms

Conditions

Carcinoma, Hepatocellular; Liver Neoplasms

Interventions

3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Study Officials

• Micheal Lilly, MD

  Medical University of South Carolina

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 12, 2016
• First Posted: October 20, 2016
• Study Start: September 30, 2019
• Primary Completion: September 30, 2023
• Study Completion: January 30, 2024
• Last Updated: April 27, 2025

Record last verified: 2025-04

Locations

US (1)